CLINICAL TRIALS PROFILE FOR BRAVELLE
✉ Email this page to a colleague
All Clinical Trials for BRAVELLE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00680238 ↗ | Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G) | Completed | University of Stellenbosch | N/A | 2004-06-01 | Objective: To compare pregnancy rates and implantation rates when embryos are selected based on a single Day 3 (D.3) score vs. a GES score plus sHLA-G expression. |
| NCT00971152 ↗ | Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle | Completed | Ferring Pharmaceuticals | Phase 3 | 2009-09-01 | This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily dose is administered for women who are at risk of a poor ovarian response in order to determine if one dose or the other results in improved cycle outcomes. |
| NCT00971152 ↗ | Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle | Completed | Clinique Ovo | Phase 3 | 2009-09-01 | This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily dose is administered for women who are at risk of a poor ovarian response in order to determine if one dose or the other results in improved cycle outcomes. |
| NCT00971152 ↗ | Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle | Completed | OVO R & D | Phase 3 | 2009-09-01 | This goal of this study is to evaluate the outcomes from in vitro fertilization cycles where a 450 IU daily dose of gonadotropins is administered compared to those where a 600 IU daily dose is administered for women who are at risk of a poor ovarian response in order to determine if one dose or the other results in improved cycle outcomes. |
| NCT01354886 ↗ | Single Dose FSH-GEX™ in Healthy Volunteers | Completed | Glycotope Biotechnology GmbH | Phase 1 | 2011-04-01 | The aim of the current study was the pharmacokinetic and pharmacodynamic characterization of a single dose administration of four doses of FSH-GEX™ in healthy pituitary-suppressed female volunteers, in comparison with two marketed comparator products. |
| NCT01354886 ↗ | Single Dose FSH-GEX™ in Healthy Volunteers | Completed | Glycotope GmbH | Phase 1 | 2011-04-01 | The aim of the current study was the pharmacokinetic and pharmacodynamic characterization of a single dose administration of four doses of FSH-GEX™ in healthy pituitary-suppressed female volunteers, in comparison with two marketed comparator products. |
| NCT01417195 ↗ | Menopur Mixed Protocol | Completed | Ferring Pharmaceuticals | Phase 4 | 2011-07-01 | The objective of this study was to compare the fertilization rate between the combination of Menopur and Bravelle mixed in the same syringe and Menopur alone, both administered subcutaneously (SC), in subjects undergoing Assisted Reproductive Technology (ART). Additionally the study assessed subjects' ability to mix and store the combination of Menopur and Bravelle and to assess safety of the Menopur and Bravelle combination. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BRAVELLE
Condition Name
Clinical Trial Locations for BRAVELLE
Trials by Country
Clinical Trial Progress for BRAVELLE
Clinical Trial Phase
Clinical Trial Sponsors for BRAVELLE
Sponsor Name
